Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)

Status Completed

Clinical Trial Summary

The investigators hypothesize that long-term disease-free survival (DFS) in patients with JMML can be achieved with a treatment of busulfan (BU), cyclophosphamide (CY) and melphalan (L-PAM) followed by hematopoietic cell transplantation (HCT).

Clinical Trial Description

Prior to transplantation, subjects will receive BUSULFAN via the central venous line, six times a day for four days, CYCLOPHOSPHAMIDE via the central venous line once a day for two days, and MELPHALAN via the central venous line for one day. Busulfan, cyclophosphamide, and melphalan are given to destroy the subject's leukemia. As well, these drugs will destroy the subject's own immune system to help ensure the new bone marrow takes and grows after transplantation. On the day of transplantation, bone marrow or umbilical cord blood from the donor will arrive to the bone marrow transplant unit and be transfused via venous line. These new cells will replace the subject's bone marrow. ;

Study Design

Related Conditions & MeSH terms

Juvenile Myelomonocytic Leukemia
Leukemia
Leukemia, Myelomonocytic, Acute
Leukemia, Myelomonocytic, Chronic
Leukemia, Myelomonocytic, Juvenile

Clinical Trial Details

NCT number	NCT00167219
Study type	Interventional
Source	Masonic Cancer Center, University of Minnesota
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	November 18, 1999
Completion date	August 9, 2023

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03190915` - Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia	Phase 2
Completed	`NCT01093586` - Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Phase 2
Completed	`NCT00078858` - Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant	Phase 1/Phase 2
Completed	`NCT01020539` - Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia	Phase 1
Terminated	`NCT00852709` - Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias	Phase 1
Active, not recruiting	`NCT01036009` - A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies	Phase 2
Completed	`NCT00898079` - Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
Completed	`NCT00112593` - Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer	N/A
Completed	`NCT01445080` - Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia	Phase 1/Phase 2
Recruiting	`NCT05800210` - Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases	Phase 2
Completed	`NCT04082286` - Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia	Phase 1
Terminated	`NCT00669890` - Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML	Phase 1
Completed	`NCT00152139` - Stem Cell Transplantation for Patients With Hematologic Malignancies	Phase 3
Completed	`NCT00006251` - Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer	Phase 1/Phase 2
Recruiting	`NCT05735717` - MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies	Phase 2
Recruiting	`NCT03843528` - Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation	Phase 1
Recruiting	`NCT03314974` - Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders	Phase 2
Active, not recruiting	`NCT02338479` - Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Completed	`NCT01305200` - Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant	Phase 3
Completed	`NCT00697671` - Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies	Phase 1